Latest News

November 24, 2017
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
November 23, 2017
This Thanksgiving, families will discuss of end-of-life care wishes; FDA provides new guidance for development of abuse-deterrent opioids; Missouri reverses its restrictive policy in Medicaid for hepatitic C medicine. 
November 22, 2017
Roche is suing Pfizer to block the company from selling a biosimilar referencing its breast-cancer drug Herceptin in the United States, claiming that the biosimilar infringes on 40 of its patents.
November 22, 2017
Consolidation is happening all throughout the healthcare industry in the United States, but the shift to consolidation in dermatology began to pick up speed in just the last 3 to 5 years and it has been driven by private investors, according to a new Viewpoint in JAMA Dermatology.
November 22, 2017
David Dale, MD, professor, internal medicine, University of Washington Medical Center, dicusess diagnosing neutropenia and its symptoms; the causes of neutropenia; when neutropenia becomes dangerous and requires hospitalization; and the costs associated with neutropenia in an interview with The American Journal of Managed Care®.
November 22, 2017
Massachusetts is trying to get a federal exemption to alter its Medicaid program; patients waiting for disability benefits get stuck in a huge backlog; and companies are preparing to increase collection and use of real-world evidence.
November 22, 2017
The Beyond A1C movement seeks regulatory and clinical are frameworks that recognize the day-to-day measures that matter to patients, such as how often they experience hypoglycemia. 
November 22, 2017
Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.
November 21, 2017
An early-stage trial in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has found that modifying the chimeric antigen receptor (CAR) T cells to target the CD22 receptor achieved remission.
November 21, 2017
Roche announced that its phase 3 IMpower150 study determined that the combination of drug atezolizumab (Tecentriq) to bevacizumab (Avastin) with the chemotherapy drugs paclitaxel and carboplatin showed a significant reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of patients with non-small cell lung cancer (NSCLC).
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!